Request Strategic Dialogue → Arrange Dayi-Anren Site Visit
THE ARTEMIS BIOTECH BRIDGE™

Unlocking the Chengdu-Dayi-Anren (CDA) biotech corridor for global markets

Peptide therapeutics, GLP-1 agonists, and biologics manufacturing. 60% of global peptide APIs produced in the Chengdu-Dayi-Anren (CDA) corridor.

Beijing policy coordination · Chengdu-Anren manufacturing delivery · 20 years of regulatory fluency

Request Peptide Technical Datasheet → Arrange Dayi-Anren Site Visit
33Partner Ecosystem
60%Global APIs
20Years in China
16Export Nations
↓

Investment Thesis

Rothschild Biotech is a Western-facing platform connecting global biotech markets with the Chengdu-Dayi-Anren (CDA) corridor.

Sichuan is positioned as a national biotech hub for peptide therapeutics, biologics, and gene therapy manufacturing. We are positioned at the center of this strategic priority, with 20 years of regulatory fluency and established presence in the CDA corridor's supply chain.

Our flagship capabilities - peptide therapeutics and GLP-1 agonists - represent a world-class peptide manufacturing ecosystem. A significant share of global peptide APIs is produced in the CDA corridor. 3+ metric tons annual capacity. FDA Green-List certified.

"China's biotech economy is projected to reach $50B+ by 2030. We are positioned to capture a significant share through our established presence in the CDA corridor."

- Dr. Michael Rothschild MD

Peptide Therapeutics

Peptide API manufacturing. GLP-1 agonists, biologics, and gene therapy capabilities. FDA Green-List certified.

Specification Peptide API Manufacturing
Annual Capacity3+ metric tons
Key ProductsSemaglutide - Tirzepatide - Retatrutide - GLP-1 Agonists
Manufacturing Facilities12 cGMP facilities - FDA Green-List
Global Market PositionSignificant share of global peptide APIs
Supply Chain100% localized - 40% cost advantage
Export Countries50+ countries served
Regulatory StatusFDA Green-List - NMPA Certified - cGMP Compliant

Global Agent and Distribution: Rothschild Biotech holds international agency rights for peptide API manufacturing across markets outside China.

Peptide Therapeutics

GLP-1 agonists, metabolic peptides, and oncology peptides. 3+ metric tons annual capacity. Significant global market share.

cGMP Manufacturing

12 FDA Green-List facilities. Full cGMP compliance. World-class quality systems. 40% cost advantage.

Global Reach

Export to 50+ countries. 100% local supply chain. Complete vertical integration from R&D to commercial deployment.

The Biotech Partner Network

The Artemis Biotech Bridge™ is building a tiered ecosystem across the CDA corridor. Current engagements span early discussions through confirmed partnerships.

✓ Confirmed Partner: Profile available under NDA.

○ 32 additional partners in discussion. Profiles available under NDA.

Tier 1
National Flagships
4 partners · 1 Confirmed · 3 In Discussion
State-level primes and national flagship manufacturers with direct access to China's biotech programs. Profiles available under NDA.
Request Details →
Tier 2
Local Manufacturers
12 partners · All In Discussion
Private manufacturers with international certifications (FDA, EU GMP) providing peptide synthesis, biologics, and API capacity. Profiles available under NDA.
Request Details →
Tier 3
R&D & Testing
17 partners · All In Discussion
Government-affiliated certification centers, testing institutions, and R&D partners supporting the CDA corridor ecosystem. Profiles available under NDA.
Request Details →
Request Partner Details →

The Chengdu Biotech Belt

China - Sichuan Province CHENGDU Biotech Capital Rothschild HQ 333 Anren - Dayi Beijing - Policy Hub Shanghai Hong Kong Legend Biotech Belt Rothschild HQ Major Hubs

Established presence in the CDA corridor - a national biotech hub

The CCPFL Doctrine
"The crest is not a symbol of privilege. It is a symbol of duty." - Dr. Michael Rothschild MD
C Class Dignity - Refinement - Education
C Culture Heritage - Tradition - Global
P Polite Society Dialogue - Respect - Civility
F Family Generations - Stewardship
L Legacy Archive - Future - Eternal
The permanent governance framework for multi-generational industrial stewardship - Since 2007

The Rothschild Family

Multi-generational stewardship. Austrian-Vienna branch. CCPFL governance.

The Rothschild Legacy

Dr. Michael Rothschild MD, representing the Austrian-Vienna branch of the Rothschild family, is building a multi-generational legacy in China rooted in the CCPFL Doctrine - Class, Culture, Polite Society, Family, and Legacy.

His children, China Jade Rothschild (born February 22, 2024 in Panyu, Guangzhou, China) and Melina Ivy Rothschild (born August 2026 at Dayi Maternal and Child Health Hospital, Dayi, Chengdu, China), represent the next generation. Both are MADE IN CHINA — born in China and being raised in Chengdu, immersed in Chinese culture and the CCPFL values that guide the Artemis Biotech Bridge™ ecosystem.

"We are not building for ourselves. We are building for our children, and their children, and all the generations to come." - Dr. Michael Rothschild MD

Disclaimer: Rothschild Biotech represents the Austrian-Vienna branch of the Rothschild family, operating independently in China. This platform is fully independent from modern-day European Rothschild-group banking entities. It bears no affiliation or connection with Lafite-Rothschild wine-marketing operations. All business activities are conducted by Rothschild (Chengdu) Technology Co., Ltd. under PRC law.

Rothschild Intelligence Library

Featured Research Reports

Institutional-grade research covering the CDA corridor, peptide therapeutics, biologics manufacturing, and the Artemis Biotech Bridge™ initiative. Five featured reports are shown below. The complete library catalog is available to qualified institutional partners.

Request Complete Library Catalog →

Investor Data Room

Comprehensive due diligence materials, financials, and operational data are available to qualified institutional partners under NDA.

Request Data Room Access →

Request Peptide Information

How can we build a legacy together?

There is no web submission form on this site.
To make inquiries, reach out via LinkedIn, direct email, or WeChat using the Chinese mobile number below.
Please include a brief background about your organization and your interest in peptide therapeutics / Artemis Biotech Bridge™ within your initial message.

LinkedIn

Dr. Michael Rothschild MD

Preferred for institutional inquiries

Email

biotech@rothschildcorp.com

For documented correspondence

WeChat

+86-189-2244-4800

For China-based partners

Address

333 Yingbin Road Section 1, Anren Town
Dayi County, Chengdu
Sichuan 611330, PRC

Note: WeChat is for China-based institutional partners only. International inquiries should use LinkedIn or email.

Connect With Us

We respond to all inquiries within 48 hours.

Our Digital Ecosystem

Rothschild Biotech is the flagship life sciences platform within a broader ecosystem of six interconnected divisions spanning biotech, clean energy, aerospace, policy, and commerce. Each division operates independently while leveraging shared resources, regulatory expertise, and the CCPFL governance framework.

Corp HQ — Group Headquarters & Manufacturing
rothschildcorp.cn
The operational nerve center of the Rothschild ecosystem in China. Based in Chengdu-Anren, Corp HQ oversees manufacturing, supply chain integration, and group-wide strategic coordination across all divisions.
Key Functions: Manufacturing · Supply Chain · Group Strategy · Governance
Visit Corp HQ →
Beijing — Policy & Institutional Liaison
rothschild.bj.cn
The policy bridge between the Rothschild ecosystem and Chinese regulatory authorities. Beijing serves as the primary liaison for NMPA, FDA, and other government relations.
Key Functions: Regulatory Affairs · Government Relations · Policy Strategy
Visit Beijing →
Shanghai — Commercial & Finance Hub
rothschild.sh.cn
The commercial and financial engine of the ecosystem. Shanghai hosts investor relations, capital markets activities, and commercial partnerships with global institutions.
Key Functions: Investor Relations · Capital Markets · Commercial Partnerships
Visit Shanghai →
Space — Aerospace Division
rothschildspace.com
The aerospace innovation arm of the Rothschild ecosystem. Space focuses on autonomous flight systems, UAV manufacturing, and the intersection of aerospace with biotech and clean energy applications.
Key Functions: Autonomous Flight · UAV Manufacturing · Low-Altitude Logistics
Visit Space →
Hydrogen — Clean Energy Division
rothschildhydrogen.com
The clean energy division of the Rothschild ecosystem. Hydrogen develops and deploys green hydrogen solutions for industrial and energy applications, including H-Brick storage, fuel cells, and sustainable energy systems.
Key Functions: H-Brick Storage · Green Hydrogen · Fuel Cells · Sustainability
Visit Hydrogen →
Biotech — Life Sciences Division
rothschildbiotech.com
The flagship life sciences platform of the Rothschild ecosystem. Biotech specializes in peptide therapeutics, GLP-1 agonists, and biologics manufacturing in the Chengdu-Dayi-Anren corridor.
Key Functions: Peptide APIs · GLP-1 Agonists · Biologics Manufacturing · CDMO
Current Site

Ecosystem at a Glance

Divisions: 6 Partners: 33+ Reports: 999+ Nations: 16 Governance: CCPFL Doctrine Founded: 2006 Years in China: 20+